Results 41 to 50 of about 290,432 (308)

Myocardial Ischemia and Reperfusion Leads to Transient CD8 Immune Deficiency and Accelerated Immunosenescence in CMV-Seropositive Patients [PDF]

open access: yes, 2014
Rationale: There is mounting evidence of a higher incidence of coronary heart disease (CHD) in cytomegalovirus (CMV) seropositive individuals. Objective: The aim of this study was to investigate whether acute MI triggers an inflammatory T-cell ...
Bagnall, Alan   +14 more
core   +1 more source

Modulation of plant autophagy during pathogen attack [PDF]

open access: yes, 2017
In plants, the highly conserved catabolic process of autophagy has long been known as a means of maintaining cellular homeostasis and coping with abiotic stress conditions. Accumulating evidence has linked autophagy to immunity against invading pathogens,
Bozkurt, Tolga O.   +9 more
core   +1 more source

The Molecular Links between Cell Death and Inflammasome

open access: yesCells, 2019
Programmed cell death pathways and inflammasome activation pathways can be genetically and functionally separated. Inflammasomes are specialized protein complexes that process pro-inflammatory cytokines, interleukin-1β (IL-1β), and IL-18 to ...
Kwang-Ho Lee, Tae-Bong Kang
doaj   +1 more source

FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells [PDF]

open access: yes, 2014
Receptor Tyrosine Kinases (RTKs) and Focal Adhesion Kinase (FAK) regulate multiple signalling pathways, including mitogen-activated protein (MAP) kinase pathway. FAK interacts with several RTKs but little is known about how FAK regulates their downstream
A Bergmann   +86 more
core   +4 more sources

Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer 
with EGFR Mutation

open access: yesChinese Journal of Lung Cancer, 2022
The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the first line treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC), but drug resistance will be acquired within 1-2 years, and the following treatment
Yue ZHU, Zhaoxia DAI
doaj   +1 more source

The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis [PDF]

open access: yes, 2016
Although necrosis and necroinflammation are central features of many liver diseases, the role of programmed necrosis in the context of inflammation-dependent hepatocellular death remains to be fully determined.
Andreas E. Kremer   +24 more
core   +1 more source

Critical Role of microRNA-21 in the Pathogenesis of Liver Diseases [PDF]

open access: yes, 2020
MicroRNAs are small non-coding RNAs that range in length from 18 to 24 nucleotides. As one of the most extensively studied microRNAs, microRNA-21 (miR-21) is highly expressed in many mammalian cell types.
Han, Sen   +4 more
core   +1 more source

Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response

open access: yesFrontiers in Bioscience-Landmark
Lung cancer, the leading cause of cancer-related mortality worldwide, poses considerable therapeutic challenges due to the varied responses to programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors.
Yuanyuan Xu   +5 more
doaj   +1 more source

Predictive biomarkers of response to immune checkpoint inhibitors [PDF]

open access: yesFarmacia Hospitalaria, 2020
Objective: The present paper provides a literature review aimed at identifying the tumor-dependent factors capable of influencing a subject’s response to immune checkpoint inhibitors, with a special emphasis on those that may act as predictive ...
María Sacramento Díaz-Carrasco   +3 more
doaj   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

open access: yes, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth   +2 more
core  

Home - About - Disclaimer - Privacy